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Abstract
Background: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few
of these have clinical impact. This study aims to pinpoint epigenetic markers that can discriminate between
non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
The methylation status of eleven genes (ADAMTS1,  CDKN2A, CRABP1,  HOXA9, MAL,  MGMT,  MLH1,
NR3C1, PTEN, RUNX3, and SCGB3A1) was determined in 154 tissue samples including normal mucosa,
adenomas, and carcinomas of the colorectum. The gene-specific and widespread methylation status among
the carcinomas was related to patient gender and age, and microsatellite instability status. Possible CIMP
tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-,
KRAS-, and TP53 mutation status.
Results: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-
free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
Widespread methylation was found in both adenomas and carcinomas. The promoters of ADAMTS1, MAL,
and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of
microsatellite instability. In contrast, normal mucosa samples taken from bowels without tumor were
rarely methylated for the same genes. Hypermethylated CRABP1, MLH1, NR3C1, RUNX3, and SCGB3A1
were shown to be identifiers of carcinomas with microsatellite instability. In agreement with the CIMP
concept, MSI and mutated BRAF were associated with samples harboring hypermethylation of several
target genes.
Conclusion: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
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Introduction
Most cases of colorectal cancer (CRC) originate from ade-
nomas. The malignant potential of adenomas increases
with size, grade of dysplasia, and degree of villous compo-
nents,[1] along with the number and order of genetic and
epigenetic aberrations.[2] The majority (~85%) of the
sporadic carcinomas are characterized by chromosomal
aberrations, referred to as a chromosomal unstable (CIN)
phenotype, whereas the smaller group (~15%) typically
show microsatellite instability (MSI) caused by defect
DNA mismatch repair.[2] Most CIN tumors are microsat-
ellite stable (MSS). A third molecular phenotype charac-
teristic to a subgroup of CRC is the CpG island methylator
phenotype (CIMP).[3] CIMP-positive tumors display
methylation of multiple loci, are associated with proximal
location in the colon, and are often microsatellite unsta-
ble.  BRAF  mutations are restricted to CIMP positive
tumors, which may be sub-classified according to a certain
combination of epigenetic and genetic changes.[4]
Here we have compared the time of occurrence and co-
variation of multiple epigenetic markers in normal colon
samples with those of adenomas and carcinomas in order
to pinpoint early onset markers for neoplastic transforma-
tion.
Materials and methods
Tissue samples
Included in the present study are twenty-one normal
colon mucosa samples from twenty deceased, cancer-free
individuals, median age 52.5, range 33–86 (called N1
henceforth); 18 normal colon mucosa samples (N2) from
18 CRC patients, median age 70.5, range 24–89 (taken at
distance (>10 cm) from the carcinoma); 63 adenomas,
median size 8 mm, range 5–50 mm, from 52 individuals,
median age 67, range 62–72; and 52 carcinomas from 51
patients, median age 70, range 33–92. The colon, includ-
ing the rectum, is divided into proximal and distal sec-
tions; the proximal, or right side, spans from coecum to
two thirds of the way across transversum; the distal, or left
side, comprises the last third of the transversum, sigmoi-
deum, and the rectum. This division originates from the
primitive digestive tract, where the right side corresponds
from the midgut, while the left side corresponds to the
hindgut. The number of proximal versus distal samples in
the series is as follows: N1 (10 vs. 11); N2 (7 vs. 11); ade-
nomas (18 vs. 45); and carcinomas (17 vs. 35). The carci-
nomas included here are from a series evaluated to
contain on average 84% tumor cells.[5] Nine of the N2
samples correspond to nine primary tumors analyzed
here. Most of the normal colon samples (26/39) consisted
of mucosa only, whereas the remaining ones were taken
from the bowel wall. The adenomas were obtained from
individuals attending a Norwegian colonoscopy screening
program.[6] The carcinomas and the N2 samples are from
a prospective series collected from 7 hospitals in the Oslo
region of Norway.[5] The N1 samples were autopsy mate-
rial collected by one of the authors.
The MSI status was determined by use of two mononucle-
otide markers, BAT25 and BAT26, and a panel of dinucle-
otide markers. Details regarding the assessment of MSI
status are given in Additional file 1.
All samples belong to approved research biobanks and are
part of research projects approved according to national
guidelines (Biobank; registered at the Norwegian Institute
of Public Health. Projects: Regional Ethics Committee and
National Data Inspectorate).
DNA methylation analyses
DNA from all samples was bisulfite modified and subjected
to methylation specific polymerase chain reaction (MSP)
for each gene.[7,8] Two of the authors independently
scored all samples and the methylation status of all positive
samples was confirmed by a second, independent round of
MSP. If any discrepancies appeared, a third round of analy-
sis was performed. In line with consensus scoring proce-
dures, we considered carcinomas with band intensities as
strong as the positive control (++) as methylated [see Addi-
tional file 2] for the gene promoter in question, while the
benign lesions and normal mucosa were scored as positive
also when weakly methylated, i.e. (+).
For detailed MSP protocol, primer sequences, and scoring
criteria see Additional file 1. Representative MSP results
can be seen in Figure 1.
Eleven genes, ADAMTS1,  CDKN2A  (encoding
p16INK4a),CRABP1, HOXA9, MAL, MGMT, MLH1, NR3C1,
PTEN,  RUNX3, and SCGB3A1  (encoding HIN-1), were
analyzed for promoter methylation by MSP. The methyla-
tion status of ADAMTS1, CRABP1, MAL, and NR3C1 for
the present series,[9,10] and the methylation status of
CDKN2A,  MGMT, and MLH1  for the carcinomas [11]
have previously been reported.
Quantitative MSP
Primers and probes for quantitative MSP (qMSP) were
designed to specifically amplify fully methylated bisulfite-
converted complementary sequences of the promoter of
interest. The primers and probe sequences used for the
MGMT [GenBank: NM_002412] are listed in Additional
file 3. To normalize for DNA input in each sample, a ref-
erence gene (ACTB [12]) was used.
Fluorescence based real-time PCR assays were carried out
in a reaction volume of 20 μL, consisting of 16.6 mM
ammonium sulphate; 67 mM trizma preset; 6.7 mM
MgCl2; 10 mM mercaptoethanol; 0.1% DMSO; 200 μMMolecular Cancer 2008, 7:94 http://www.molecular-cancer.com/content/7/1/94
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each of dATP, dCTP, dGTP, and dTTP; 600 nM of each
primer; 0.4 μL of Rox dye; 200 nM of probe; 1 unit of plat-
inum Taq polymerase (Invitrogen, Carlsbad, CA, USA),
and 2 μl of bisulfite-modified DNA as a template. PCR
was performed in separate wells for each primer/probe set
and each sample was run in triplicate. Additionally, mul-
tiple water blanks were used, and as positive and negative
control we used commercial methylated and unmethyl-
ated DNA (Millipore, Temecula, CA, USA). A series of
dilutions of methylated DNA after bisulfite conversion
were used for constructing a standard curve to quantify
the amount of fully methylated alleles in each reaction.
All amplifications were carried out in 96-well plates on an
7000 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA), at 95°C for 2 min followed by 45
cycles of 95°C for 15 s, and 60°C for 1 min.
In order to adjust for the possible various amounts of
bisulfite treated DNA input in each PCR, the qMSP levels
were normalized against the respective values of the inter-
nal reference gene (ACTB). The ratio thus generated con-
stitutes an index of the percentage of input copies of DNA
that are fully methylated at the primer- and probe-binding
sites. The ratio was multiplied by 100 for easier tabulation
(methylation level = target gene/reference gene × 100).
A given sample was considered positive for promoter
hypermethylation when amplification was detected in at
least 2 of the triplicates of the respective qMSP analysis.
The qMSP threshold was determined by adjusting the best
fit of the slope and R2, using the calibration curve.
Selection criteria for the 11 gene promoters analyzed in 
the present study
Some of the genes analyzed were known to be targeted
through promoter methylation in cancer, including color-
ectal cancer (SCGB3A1,  RUNX3, CDKN2A, MLH1, and
MGMT). HOXA9 was a potential new methylation target
in colorectal cancer. ADAMTS1,  CRABP1,  MAL, and
NR3C1  were identified as novel epigenetically silenced
target genes in colorectal cancer by our group.[9,10,13]
They were selected to be tested in combination with
known methylated genes in a large series of colorectal
lesions to check for interdependencies. The methylation
status of all included genes was compared in a series of
normal mucosa from individuals without cancer with
those of normal, benign and malignant tissue from the
large bowel of cancer patients. Only two previous studies
have compared gene methylation among the same four
types of sample groups as investigated here.[14,15] The
first only investigated one gene and the latter 10 genes
among which only three overlapping the present selected
gene list.
Gene mutation status of BRAF, KRAS and TP53
The present carcinoma series form a part of a series previ-
ously studied for genetic changes, including BRAF, KRAS
and TP53.[23,24] The specific mutation status of the indi-
Representative methylation results in colorectal tumors and normal mucosa Figure 1
Representative methylation results in colorectal tumors and normal mucosa. Results of CDKN2A, CRABP1, HOXA9, 
and RUNX3 in selected samples are shown. Positive controls (POS): NB, normal blood, for the unmethylated reaction and IVD, 
in vitro methylated DNA, for methylated reaction. Negative controls: dH2O. U: unmethylated alleles, M: methylated alleles. The 
ladder (left lane) is the EZ Load™ 100 bp Molecular Ruler (BioRad, Hercules, CA, USA).Molecular Cancer 2008, 7:94 http://www.molecular-cancer.com/content/7/1/94
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vidual tumors included here can be found in Additional
file 4.
Statistics
The 2 × 2 contingency tables were analyzed using Fisher's
exact test and 3 × 2 tables were analyzed by the Pearson χ2
test. Non-parametric analyses were performed using the
Kruskal-Wallis and Mann-Whitney tests. An independent
T-test was performed when comparing continuous nor-
mally distributed data with two groups. The bivariate cor-
relation analysis was performed with Pearson's
correlation. In order to determine age-specific methyla-
tion for the genes we used logistic regression analysis. All
two-tailed  P-values were derived from statistical tests
using the SPSS15.0 software (SPSS, Chicago, IL, USA), and
considered statistically significant at P ≤ 0.05. The methyl-
ation heat-map was generated by average linkage hierar-
chical clustering and Pearson correlation distance
measure, using the SpotFire DecisionSite®9.0 software.
Seven individuals had multiple polyps in the colon, and
to exclude potential bias when analyzing patient data
such as sex and age, one polyp from each individual was
randomly selected for statistical analyses.
Results
MSI status of colorectal tumors
Two of sixty-three (3%) polyps displayed MSI. Both were
large (≥10 mm) and located in the proximal colon. The
carcinomas were pre-selected according to MSI-status and
27/52 (52%) were MSI-positive.
DNA promoter methylation in normal mucosa, adenomas, 
and carcinomas
The results of the MSP analyses of all samples and each
gene are summarized in Figure 2, Table 1, and Additional
file 5. The mean number of genes methylated per sample
was 0.4 for the N1 group, 1.2 for N2, 2.2 for adenomas,
and 3.9 for carcinomas, and was significantly different
among the groups using Kruskal-Wallis test; P < 0.0001
(mean rank N1, 10.2; N2, 17.3; adenomas, 23.1; and car-
cinomas, 31.4). Overall, 6/21 (29%) of the N1 samples,
9/18 (50%) of the N2 samples, 52/63 (83%) of the ade-
nomas, and 48/52 (92%) of the carcinomas, were methyl-
ated in one or more of the eleven analyzed genes.
Statistically significant differences in methylation fre-
quencies among sample groups were also evident at the
single gene level. ADAMTS1, CDKN2A, CRABP1, MLH1,
NR3C1, RUNX3, and SCGB3A1 showed increasing meth-
ylation frequencies from adenomas to carcinomas, while
HOXA9, MAL, and MGMT displayed overall equal meth-
ylation frequencies in all tumor subgroups. PTEN was
unmethylated in carcinomas, and was thus not investi-
gated in adenomas or included in the figures, tables
(except Additional file 4) or statistics.
The more frequent promoter hypermethylation found
among N2 samples compared with N1 samples was
apparent both for the total number of methylated genes,
and at the individual gene level (MGMT, P = 0.055). The
reliability of our MSP scorings was tested by quantitative
MSP analysis of one example gene performed in a blinded
manner in another lab. The results were in perfect con-
cordance [see Additional file 6].
No difference was seen in methylation frequencies
between N2 samples with corresponding MSI-positive
carcinomas (n = 6) and those with corresponding MSS
carcinomas (n = 12).
Overall, gene methylation frequencies were higher among
MSI than among MSS carcinomas, and were statistically
significant for CRABP1,  MLH1,  NR3C1,  RUNX3, and
SCGB3A1 (P ≤ 0.0001, P ≤ 0.0001, P = 0.001, P ≤ 0.0001,
and P = 0.03, respectively). Methylation of these genes
Table 1: Gene promoter methylation and microsatellite instability
ADAMTS1 CDKN2A CRABP1 HOXA9 MAL MGMT MLH1 NR3C1 RUNX3 SCGB3A1
MUM U M U M U M U M U M U M U M U M U
Sample type
N1 0 21 0 21 0 21 4 17 1 20 2 19 0 21 0 21 0 1 1 20
N2 1 17 2 16 0 18 7 11 2 16 7 10 1 17 0 18 0 1 1 17
Adenoma 23 40 10 53 7 53 22 40 45 18 23 39 0 63 2 61 4 4 4 59
Carcinomas 36 15 17 35 25 25 12 38 41 9 21 31 11 41 13 37 16 9 9 40
MSI status
Carcinomas
MSI 19 8 10 17 22 5 7 20 21 6 11 16 11 16 12 15 16 8 8 18
MSS 17 7 7 18 3 20 5 18 20 2 10 15 0 25 1 22 0 1 1 22
P value NS NS <0.0001 NS NS NS <0.0001 0.001 <0.0001 0.026
Abbreviations: M, methylated samples; U, unmethylated samples; NS, not significant; N1: non-cancerous normal samples; N2: normal samples from 
cancer patients. MSI status data is listed for the individual polyp. In some cases a patient may have several polyps.Molecular Cancer 2008, 7:94 http://www.molecular-cancer.com/content/7/1/94
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Methylation profiles of normal mucosa, adenomas, and carcinomas Figure 2
Methylation profiles of normal mucosa, adenomas, and carcinomas. Eleven genes were analyzed by MSP. Upper 
panel: non-cancerous lesions; lower panel: carcinomas stratified according to MSI-status. X-axis, the analyzed genes; Y-axis, the 
percentage of methylated samples. N1: normal colon samples from cancer-free individuals; N2: normal colon samples from 
cancer patients; MSI: microsatellite instability; MSS: microsatellite stability.Molecular Cancer 2008, 7:94 http://www.molecular-cancer.com/content/7/1/94
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showed a strong association to proximal carcinoma loca-
tion, demonstrating the close connection between high
methylation levels, proximal location and MSI (P
≤0.0001, P ≤ 0.0001, P ≤ 0.001, P = 0.001, and P = 0.04,
respectively). Association to site was also seen for HOXA9
in N1 samples (P  = 0.04). HOXA9  was also more fre-
quently methylated among non-cancerous normal
mucosa (n = 20) from older patients compared to younger
patients, indicating age-specific methylation (P = 0.025).
However, this was not confirmed among the larger group
of carcinomas (n = 52).
Interdependence among hypermethylated genes
From bivariate correlation analysis [see Additional file 7],
methylation of MLH1 was correlated with methylation of
CRABP1  (correlation coefficient 0.51; P  = 5 × 10-11),
NR3C1 (correlation coefficient 0.72; P = 1 × 10-25) and
RUNX3 (correlation coefficient 0.57; P = 6 × 10-14). Meth-
ylation of RUNX3 itself was strongly correlated to methyl-
ation of both NR3C1 (correlation coefficient 0.75; P = 5 ×
10-28) and CRABP1 (correlation coefficient 0.67; P = 3 ×
10-20). Methylation of NR3C1 and CRABP1 was also cor-
related (correlation coefficient 0.59; P = 4 × 10-15), as well
as ADAMTS1 and MAL (correlation coefficient 0.53; P = 2
× 10-12).
Hierarchical clustering of samples according to gene
methylation status showed that MLH1 and NR3C1 were
most closely related, followed by RUNX3 and CRABP1. In
contrast, HOXA9 and MGMT displayed methylation pat-
terns independent from each other and the other genes
(Figure 3).
Widespread methylation
Several samples harbored simultaneous promoter methyl-
ation of two or more of the analyzed genes [see Additional
file 8]. The distribution of methylated gene numbers per
sample did not appear to be bimodal. Neither N1 nor N2
samples displayed methylation of five or more genes, here
denoted widespread methylation. Seven of 63 (11%) ade-
nomas displayed widespread methylation, and these were
by far larger in size (mean = 19 mm) than the remaining
adenomas (mean = 10 mm; P = 0.013). In carcinomas,
widespread methylation was seen more frequently in MSI
(16/27; 59%) than in MSS (3/25; 12%) samples (P  =
0.001). All sixteen MSI samples with widespread methyl-
ation showed similar molecular profiles when DNA meth-
ylation status, TP53-, KRAS-, and BRAF-mutation status
were considered, in line with a CIMP positive phenotype
(Figure 4). The three MSS samples with widespread meth-
ylation included one tumor with TP53 mutation, one with
both TP53 and KRAS mutation and one with BRAF muta-
tion.
The distribution of the carcinomas combined with infor-
mation regarding sex, age, MSI-status, and widespread
methylation is illustrated in Figure 5. From the figure we
see that widespread methylation is associated with proxi-
mal tumors derived from elderly women.
Discussion
We demonstrate in the present study aberrant promoter
methylation of several genes, at variable frequencies, in
the stepwise development of colorectal tumors.
An association between hypermethylation and lack of
expression has previously been shown for all genes ana-
lyzed in the present study.[8-10,25-28] Although multiple
genes are methylated in a cancer, only some are function-
ally involved in tumorigenesis, [29-31] whereas others
with unknown functional contribution still may serve as
good biomarkers from a diagnostic perspective.
Comparing methylation profiles of normal mucosa, 
adenomas and carcinomas of the large bowel
The identified methylation profiles of normal colorectal
tissues, adenomas, and carcinomas demonstrated a step-
wise increase in CpG island promoter methylation
towards malignancy, indicating that their inactivation
plays a role in the progression of the tumor. This was evi-
dent both for widespread methylation and at the single
gene level (increasing frequencies of methylation from
benign to malignant stages) with the exception of
HOXA9, MAL, and MGMT. The lack of increase in methyl-
ation frequencies between non-malignant adenomas and
Methylation HeatMap Figure 3
Methylation HeatMap. Hierarchical clustering reveals that 
methylation of NR3C1 and RUNX3 are most closely related, 
followed by MLH1 and CRABP1. Methylation of MGMT and 
HOXA9 are most independent both from each other and 
from rest of the set. The genes are presented in columns, 
while the samples are presented in rows. Black, unmethyl-
ated; red, methylated; and grey, missing values.Molecular Cancer 2008, 7:94 http://www.molecular-cancer.com/content/7/1/94
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carcinomas for these three genes may suggest that they are
more important in the initiation of cancer, rather than in
progression. These genes in addition to ADAMTS1 were
also hypermethylated in comparable frequencies among
MSS and MSI carcinomas. These observations, and the fact
that the separation of the MSI- and MSS-pathway is
thought to occur early in colorectal tumorigenesis suggest
that alterations of the four genes represent early events.
ADAMTS1 is believed to be an inhibitor of both angiogen-
esis and endothelial proliferation,[32] features commonly
activated in cancer, as a tumor must turn on angiogenesis
in order to grow larger than 1–2 mm3[33]. Members of
the HOX gene family are shown to be commonly altered
in several cancers, and to the best of our knowledge, this
is the first report of HOXA9 methylation in colorectal neo-
plasms.  HOXA9  methylation has received increasing
interest in recent time as it is included in the HOXA-clus-
ter which harbors methylation over a larger area than just
a single promoter, indicating that methylation may mimic
genetic micro-deletions and turn off a cluster of genes
rather than just one at the time, i.e. yet another example
of long range epigenetic silencing. [34-36]. MAL  is
involved in T-cell differentiation, especially in the late or
intermediate stages.[37] It is also involved in polarization
of epithelial cells caused by apical transport of lipids and
proteins. Loss of cell polarity is often seen in neoplastic
transformation.[38] For MGMT the early involvement is
further supported by the fact that promoter methylation
has previously been identified in aberrant crypt foci.[39]
Our data do not suggest that any of the markers included
here were methylated in an age dependent manner. Of the
11 analyzed genes, six were unmethylated in all normal
samples from non-affected individuals, excluding them as
age-specific methylation targets. For two genes (SCGB3A1
and  MAL) only one of 21 samples was methylated.
Genetic and epigenetic changes in colorectal carcinomas with known microsatellite status Figure 4
Genetic and epigenetic changes in colorectal carcinomas with known microsatellite status. The results are visual-
ized according to genetic (top part of the figure) and epigenetic changes (lower part of the figure). The results are organized 
according to MSI, followed by BRAF-, KRAS-, TP53- and methylation-status of the MSI associated genes.
Distribution of colorectal carcinomas according to site asso- ciates with sex, age, MSI-status and methylation frequencies Figure 5
Distribution of colorectal carcinomas according to 
site associates with sex, age, MSI-status and methyla-
tion frequencies. The circles indicate 52 carcinomas placed 
according to site, the red circle = female, the blue = male. 
Top right section of the circle: blue = MSS, red = MSI. The 
lowest section: green = patient <68 years of age, yellow = 
patient ≥ 68 years. Widespread methylation is given in the 
top left section: white = methylation in < 5 genes, black = 
widespread methylation ≥ 5 genes.Molecular Cancer 2008, 7:94 http://www.molecular-cancer.com/content/7/1/94
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Although the sample in question was from an older indi-
vidual (75 years), the resulting overall methylation fre-
quency was only 5%. This is in strong contrast to the
frequent reported age-specific methylation of the N33
gene, which shows approximately 46% methylation
among normal samples in general and 58% methylation
in normal samples from individuals over 60
years.[40]HOXA9 is the only gene in the present study
harboring "frequent" promoter methylation in normal
samples (19% overall, and 43% for individuals of 60 years
or older). Binary regression analysis resulted in a signifi-
cant P  value, however, when using the same statistical
analysis in the tumor sample series age dependence could
not be confirmed. Both technical and biological aspects
influence the interpretation of DNA promoter methyla-
tion analyses.
The importance of primer design is emphasized in the
PTEN  assay. Promoter hypermethylation of PTEN  has
been frequently reported in various tumor types, includ-
ing CRC. [16-19] However, the majority of MSP primer
sets used have failed to discriminate between PTEN and its
frequently methylated pseudogene, leading to a high rate
of false positives.[20] In the present study, we used MSP
primers specifically designed to amplify the protein-
encoding PTEN gene,[21] and showed that PTEN was not
subject to promoter hypermethylation in colorectal carci-
nomas. A novel study confirms that methylation of PTEN
is an unusual event in colorectal cancer as a whole.[22]
Interdependence among hypermethylated genes and 
widespread methylation
The hierarchical clustering analysis of gene promoter
methylation status in normal, benign, and malignant
samples confirmed that the distribution of HOXA9 and
MGMT  methylation frequencies across sample groups
differed from the other genes. Overall, methylation of
NR3C1 and RUNX3 had the highest correlation (Figure
3 and Additional file 7), in addition to MLH1, which was
also closely related to NR3C1 and RUNX3. Furthermore,
the present study confirmed that hypermethylation of
MLH1 was characteristic of right-sided sporadic colon
tumors with MSI.[41] The lack of MLH1 hypermethyla-
tion in adenomas analyzed in the present study supports
the theory that CIMP and MSI-tumors arise from sessile
serrated polyps rather than from adenomas.[42]NR3C1,
RUNX3,  CRABP1, and SCGB3A1  were also shown to
have the same characteristics as MLH1, supporting the
hypothesis that DNA methylation plays a more promi-
nent role in proximal than in distal carcinogenesis.
CRABP1, MLH1, NR3C1, and RUNX3 have recently been
shown to belong to a panel of epigenetically regulated
genes which best discriminate between CIMP-positive
and CIMP-negative tumors, a phenotype strongly related
with MSI status.[43]
We found that the MSI positive samples with V600E BRAF
mutations were accompanied by promoter hypermethyla-
tion of several genes, in agreement with the CIMP pheno-
type (Figure 4). Furthermore, we also confirmed that MSS
tumors with TP53 mutations had less overall methylation,
and thus in agreement with a CIMP negative phenotype.
KRAS mutations were evenly distributed between MSI and
MSS samples but seemingly the KRAS/MSI samples had
more methylation than KRAS/MSS samples. Interestingly,
three MSS samples had BRAF mutations, and all differed
from the V600E mutation found among the MSI tumors.
Methylation markers suitable for early tumor detection
For genes previously analyzed for promoter methylation
in normal colon samples, our results are within the
expected range (CDKN2A, 0–33% (range of samples 9–
100, total methylation frequency ~4%) [44-57]; MGMT,
0–39% (range of samples 12–220, total methylation fre-
quency ~7%)[14,15,44,49,50,53,56-61]; and MLH1, 0–
50% (range of samples 8–100, total methylation fre-
quency ~5%)).[44,46,49,50,52,53,55-57,62-
67]SCGB3A1 and RUNX3 have previously been analyzed
in only one study, and both were unmethylated in 57 nor-
mal samples.[48] The study showing the highest methyla-
tion frequency of CDKN2A  and  MLH1  were biased
towards normal samples taken distant from MSI- and
CIMP-positive tumors,[46] thus a higher degree of meth-
ylation might be expected.
A suitable, highly specific, biomarker should be unmeth-
ylated in normal mucosa from healthy individuals and
frequently methylated in carcinomas, and possibly also in
benign lesions. To date, only few such markers have been
identified,[10,68,69] and one of the most suitable ones,
Vimentin, is non-expressed in a normal, healthy,
colon.[69] The fact that an important biomarker is non-
expressed in normal tissue supports the choice of a low
threshold for methylation positive early lesions, applied
in the present search for early onset biomarkers. Hyper-
methylation of genes such as ADAMTS1 and MAL are also
suitable biomarkers for early detection, as they are infre-
quently methylated in normal mucosa taken from indi-
viduals without cancer (0% and 5%, respectively), but
highly methylated in malignant lesions (71% and 82%,
respectively)[9,13]. In addition, both are frequently
hypermethylated among the adenomas (37% and 71%,
respectively) independent of size. Of course, sufficient
sensitivity and specificity of these hypermethylation
markers must be shown in feces or blood samples for the
purpose of non-invasive testing. It should be note that thisMolecular Cancer 2008, 7:94 http://www.molecular-cancer.com/content/7/1/94
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is an obstacle yet to be overcomed by suggested markers
in existing non-invasive tests.
It has been speculated that methylation of specific genes,
such as MGMT, may yield a so-called "field effect", provid-
ing favorable conditions for further alterations which
eventually might lead to tumor formation.[58,70] The ini-
tial steps in tumorigenesis might be due to an epigenetic
disruption of a progenitor/stem cell which may be fol-
lowed by genetic mutations of gatekeeper genes, and the
subsequent acquisition of other genetic and epigenetic
alterations.[71] This model provides a possible explana-
tion of why we see relatively high methylation frequencies
for genes such as MGMT, and HOXA9 in normal samples
taken from cancer patients.
Summarized, this study has shown that gene-specific pro-
moter hypermethylation is an early event in colorectal
tumorigenesis, exemplified by hypermethylation of
MGMT  in adenomas and normal mucosa from cancer
patients, and by the high frequency of ADAMTS1  and
MAL  methylation in polyps irrespective of size. These
markers are suitable as part of a panel aiming at detecting
early colorectal lesions, and possibly a field effect in a
"labile" colon. In general, we saw that aberrant CpG
island hypermethylation increased with malignancy.
Finally, methylation of CRABP1, MLH1, NR3C1, RUNX3,
and SCGB3A1 were identifiers of MSI carcinomas.
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